However, chronic rapamycin treatment inhibits both mTORC1 and mTORC2 activity and its clinical use is associated with significant side effects. With the development of novel mTORC1-selective compounds ...

In the article by Min et al, “mTORC1 Signaling in Brain Endothelial Progenitors Contributes to CCM Pathogenesis,” which was published ahead of print on July 3, 2024, and appeared in the August 2, 2024 ...